Study details
Enrolling now
TB006 Trial for Autism Spectrum Disorder
Rossignol Medical Center
NCT IDNCT06500637ClinicalTrials.gov data as of Apr 2026
Phase
Phase 2
Target enrollment
45
Study length
about 2 years
Ages
18–35
Locations
2 sites in AZ, CA
What this study is about
Researchers are testing a new medication, TB006, to treat autism spectrum disorder. The trial will last 727 days and involve adults. Participants will be randomly assigned to receive either TB006 or a placebo.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take TB006
Participation Burden
What's physically and logistically required of participants.
Logistics & Travel
In-person visits
Requires travel to a study site
Physical Intervention
Standard
How treatment is administered
Treatment Assignment
Randomized & Blinded
You may get a placebo/standard care, and you won't know which.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Body systems
Psychiatry / Mental Health